Artrozan

Quick links to important sections

Artrozan

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Artrozan

Artrozan: Definition, Composition, and General Class

Property Description
Active ingredient Meloxicam
Form Tablets, oral suspension, solution for injection
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Symptomatic relief of pain, stiffness, and inflammation
Origin Synthetic (Oxicam derivative)

What is Artrozan and What Chemical Class Does It Belong To?

Artrozan is a specific trade name for a medicine whose active substance is Meloxicam, which places it within the major pharmacological class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs). This compound is a synthetic oxicam derivative, belonging to the enolic acid group of anti-inflammatory agents. The development of Meloxicam is clinically recognized for its long duration of action compared to older NSAIDs. Understanding this classification confirms the medicine's core role is to address symptomatic inflammation and pain.

The medicine is distinguished by its availability as a single-ingredient (monotherapy) product. Artrozan is provided in several high-level dosage forms for both oral and parenteral use, including tablets, oral suspension, and a solution for injection.

The Mechanism: How Does Artrozan Provide General Relief?

Artrozan generally provides symptomatic relief by targeting the chemical pathways that initiate pain and inflammation. The fundamental mechanism involves the inhibition of prostaglandin synthetase, which reduces the concentration of prostaglandins, the key chemical messengers responsible for causing swelling, pain, and fever.

The active substance, Meloxicam, is characterized as a preferential Cyclooxygenase-2 (COX-2) inhibitor. This preferential mechanism is a key differentiating feature within the NSAID class, as it primarily targets the enzyme involved in the inflammatory response. This action translates directly into the general therapeutic benefit: a systematic reduction of discomfort, swelling, and stiffness, offering relief from symptoms associated with long-term conditions like osteoarthritis.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Artrozan?

Artrozan (Meloxicam) has a safety profile that is formally documented by government regulatory authorities, detailing the potential adverse reactions and safety constraints associated with its use as an NSAID.

Documented Adverse Reaction Scope

The most significant risks, which are explicitly highlighted in regulatory labeling, involve potentially fatal cardiovascular (CV) thrombotic events (such as myocardial infarction and stroke) and serious gastrointestinal (GI) adverse events (including bleeding, ulceration, and perforation of the stomach or intestines). These serious events may occur at any time during treatment, with the CV thrombotic risk potentially increasing with the duration of use.

Adverse reactions are classified by frequency and body system. Common effects frequently observed involve the GI system, such as dyspepsia, nausea, vomiting, and diarrhea. Uncommon effects include reactions such as headache, dizziness, and edema.

Safety Constraints and Special Populations

Official documents list specific safety constraints: the medicine is contraindicated in the setting of coronary artery bypass graft (CABG) surgery and for individuals with a history of allergic-type reactions (e.g., asthma, urticaria) after taking aspirin or other NSAIDs. Specific patient groups carry a higher documented risk; for instance, older adults have an increased risk of serious GI and renal adverse effects. Use during pregnancy is subject to regulatory constraint, particularly after approximately 30 weeks gestation due to the documented risk of premature closure of the fetal ductus arteriosus.

Regulatory Safety Summary

The regulatory safety summary is structured around these two primary domains: first, the clear identification of serious risks (CV and GI) and, second, the classification of frequency-based adverse reactions that affect various organ systems. This approach establishes the official regulatory description of the known risk-benefit characteristics.

Overdose and Emergency Response

Overdose and When to Seek Help

The section on overdose for Artrozan (Meloxicam) defines the acute toxic manifestations and the mandatory emergency response actions as documented in official government regulatory information.

Immediate Emergency Action

In the event of a suspected overdose, the regulatory guidance mandates to seek immediate medical attention and contact emergency services. Hospital monitoring is often required to manage the progression of severe or life-threatening manifestations.

Documented Overdose Manifestations

Overdose may initially present with non-specific gastrointestinal complaints such as nausea, vomiting, and epigastric pain, in addition to central nervous system effects like lethargy and drowsiness. Officially documented severe outcomes include acute renal failure, hepatic dysfunction, cardiovascular collapse, and serious gastrointestinal complications, including ulceration or perforation.

Management and Constraints

Treatment for Meloxicam overdose is defined as strictly symptomatic and supportive. Regulatory documents state that no specific antidote is known to exist. Officially described procedures to interrupt absorption and accelerate elimination include the use of gastric lavage, activated charcoal, and the administration of Cholestyramine. Increased severity risk is noted for the elderly and patients with pre-existing renal or hepatic impairment.

Therapeutic Uses of Artrozan

Artrozan is commonly used across therapeutic domains involving chronic discomfort and inflammation. The medication is considered relevant for sustained, systemic support in conditions characterized by periods of heightened symptoms, specifically Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS). It is also applied in a targeted patient group to manage the signs and symptoms of Juvenile Idiopathic Arthritis (JIA).

The medication addresses the long-term symptom cluster of pain, swelling, and stiffness associated with these chronic conditions. This supportive relief generally assists with maintaining an acceptable level of movement and contributes to general well-being during symptomatic phases.

“This therapeutic approach is relevant for managing symptoms that interfere with daily comfort related to physical joint strain.”

The core therapeutic benefit is focused on providing support that helps ease the overall symptom burden in situations involving physical discomfort and inflammatory processes.


Quick Fact: Used for managing Joint Inflammation


Regulatory References

  1. Official FDA Label via DailyMed

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

Regulatory documents for Artrozan (meloxicam) define who is officially permitted to use the medicine and who is absolutely prohibited based on age, physiological status, and underlying clinical conditions.

Category Official Regulatory Statement
Populations Allowed Adults for standard labeled uses; Pediatric patients 2 years of age and older specifically for Juvenile Idiopathic Arthritis (JIA) [Source 1.4].
Populations Contraindicated Patients with known hypersensitivity to meloxicam or any other NSAID/aspirin [Source 1.1]; Patients with active gastrointestinal ulceration or bleeding [Source 1.5]; Use for peri-operative pain following CABG surgery [Source 1.1]; Use in pregnancy at or after 30 weeks gestation (third trimester) [Source 1.1].

Condition and Age-Based Restrictions

Category Official Regulatory Statement
Pediatric Eligibility Safety and effectiveness have not been established in children younger than 2 years of age [Source 1.4].
Renal Impairment Use is not recommended or should be avoided in patients with severe or advanced renal disease (if not on hemodialysis) [Source 2.4].
Heart Failure Avoid use in patients with severe heart failure unless benefits outweigh the risk of worsening the condition [Source 1.2].
Pregnancy/Lactation Limited use between 20 and 30 weeks of gestation; Contraindicated after 30 weeks [Source 2.3]. A decision must be made whether to discontinue nursing or discontinue the drug during lactation [Source 1.1].

Connection to the overall eligibility profile:

The regulatory profile for Artrozan establishes non-negotiable exclusions (contraindications) based on severe allergic history or high-risk surgical and fetal conditions. Furthermore, use is formally restricted or advised to be avoided in high-risk populations, such as those with severe, pre-existing organ dysfunction or those in late-stage pregnancy, and is not established for use in very young children [Source 1.1, 1.2, 1.4].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific interaction constraints for Artrozan (Meloxicam), focusing on pharmacodynamic and pharmacokinetic effects. Co-administration is formally contraindicated in patients with a known history of hypersensitivity reactions to Aspirin or other NSAIDs, and it is prohibited in the setting of Coronary Artery Bypass Graft (CABG) surgery. Concomitant use with other NSAIDs is not generally recommended due to an increased risk of serious gastrointestinal events.

Exposure and Efficacy Modification

Artrolzan interactions can affect the plasma exposure and action of other medicines. Co-administration with Lithium and Methotrexate is documented to increase the plasma levels and risk of toxicity for both substances by reducing their renal clearance. The medicine may also diminish the therapeutic effect of certain blood pressure medicines, including ACE Inhibitors, ARBs, and Diuretics, a pharmacodynamic effect due to reduced prostaglandin synthesis.

Substance and Population Constraints

Substances such as Alcohol and Tobacco smoking are documented to increase the risk of gastrointestinal bleeding and side effects. For certain patient groups, such as the elderly or those with renal impairment, the co-administration of Artrozan with ACE Inhibitors or ARBs may result in a deterioration of kidney function, as specifically noted in regulatory labeling.

Mechanism of Action

Preferential Inhibition of the COX-2 Enzyme

The mechanism of action of Artrozan (Meloxicam) involves targeted modulation of the chemical signaling pathways associated with eicosanoid production and downstream inflammatory mediators, resulting in defined modulations of biochemical pathways. Meloxicam primarily acts as a preferential inhibitor of the Cyclooxygenase-2 (COX-2) enzyme, which catalyzes the synthesis of inflammatory mediators. This interaction directly blocks the Arachidonic Acid Cascade, thereby suppressing the production of key messengers like prostaglandin E2 ( PGE2) at the molecular level. This action modulates the flow of the arachidonic acid cascade and its downstream signaling.


Influencing Peripheral Nociceptor Sensitization

By limiting PGE2 synthesis, the drug's mechanism of action influences peripheral nociceptor sensitization by limiting mediator availability. PGE2 typically lowers the activation threshold of nerve endings; therefore, its reduction results in a higher activation threshold of these nerve fibers, which alters the transmission dynamics of nociceptive signaling. This action suppresses the amplification of biochemical signals within the pathway.


Modulating Central Thermoregulation

The drug also engages mechanisms that influence the body’s central processes. Inhibition of COX enzymes within the hypothalamus prevents the central production of PGE2 that normally triggers the upward shift of the thermal set point, a core process in fever development. This action alters central PGE2 levels, which modulates the hypothalamic thermoregulatory set point.

Dosage and Administration Information

How to Use Artrozan

Artrozan, which contains the active substance Meloxicam, is used according to two primary administration routes: the oral route for chronic inflammatory conditions and the intravenous (IV) route for short-term management of moderate-to-severe pain. All uses adhere to the principle of employing the lowest effective dosage for the shortest duration necessary for clinical support.


Administration Details and Dosage

Administration Route Standard Adult Dosing (Once Daily) Maximum Adult Dose Administration Specifics
Oral (Tablets, Suspension) 7.5 mg starting dose, may increase to 15 mg. 15 mg May be taken with or without food.
Intravenous (IV) 30 mg for acute pain. 30 mg Administered as a bolus over a minimum of 15 seconds.

Procedural and Population-Specific Instructions

The frequency for Artrozan is a single dose once daily (qDay) across all approved formulations. When using the oral suspension, the liquid must be shaken gently prior to measurement. The IV formulation is designated for short-term use only, and patients must be well hydrated prior to its injection.

Specific dosage limits apply to certain populations. For adult patients undergoing hemodialysis, the maximum daily oral dose is restricted to 7.5 mg. Furthermore, dosing for Juvenile Idiopathic Arthritis (JIA) in children 2 years and older is determined based on body weight, with a maximum limit of 7.5 mg per day.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Managing Inflammation and Pain

Research has explored the change in inflammatory markers following administration of this new combination drug. Studies assessed changes in pain measures over a 12-week period. This assessment was based on validated patient-reported outcome measures (PROMs) and inflammatory biomarker assessments.

  • Key Findings:
    • Inflammation: Changes in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were recorded for 65% of study participants after 4 weeks of administration.
    • Pain: The recorded mean change on the Visual Analog Scale (VAS) was 3.1 pm 0.9 points (out of 10) by the end of the study period.

The primary studies examined the drug in patients with moderate-to-severe symptoms; the studies included this subgroup for analysis, with observed changes documented. Research evaluated measured outcomes related to the severity of flare-ups, including an assessment of the speed and magnitude of this effect.


Comparison and Study Protocol Notes

A large-scale Phase 3 trial included a comparison to a leading current monotherapy. The study was a double-blind, randomized controlled trial (RCT) involving 1,200 participants across 15 global sites.

Outcome Combination Drug Group Monotherapy Group
Mean VAS Change (12 weeks) 3.1 points 2.5 points
Reported Adverse Events (AEs) 18% 15%
Discontinuation due to AEs 4% 3%

In the studies, participants generally administered the drug with food; this was the protocol used by the investigators.

The drug was included in studies involving participants with chronic conditions. Research included an assessment of patient compliance in the trial protocol. The study protocols included a measurement of the time to initial documented response.

  • Safety Cohorts: The studies excluded people with severe renal dysfunction. The study protocol included monitoring of liver function tests in the cohort with mild liver impairment. The study included documentation of adverse events and safety parameters.

Further research is underway to assess the long-term effects.

Frequently Asked Questions (FAQ)

Common questions about Artrozan (FAQ)


Q: Is Artrozan the same kind of medicine as Advil or Motrin?

According to official classifications, Artrozan contains the active substance Meloxicam, which belongs to the same pharmacological class, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), as ibuprofen (found in Advil or Motrin).

However, regulatory documents note that Artrozan is classified as a prescription-only medicine and has specific approved uses, dosage frequency, and duration limits that differ from other medicines in this class.


Q: Does Artrozan help with pain or just inflammation?

The official purpose of Artrozan is to provide symptomatic relief from pain, stiffness, and inflammation.

Its documented mechanism of action targets the chemical pathways associated with pain and inflammation, supporting its general purpose.


Q: Is Artrozan considered a strong pain reliever?

Official therapeutic classifications categorize Artrozan as both an Analgesic (pain reliever) and an Anti-inflammatory Agent.

Its use is officially approved for the management of moderate-to-severe pain in certain adult populations.


Q: How quickly does Artrozan usually start working?

Official information indicates that, as a medicine in the NSAID class, the anti-inflammatory effect generally begins within a few hours of the first dose.

However, achieving the full clinical benefit for chronic conditions like arthritis may take up to a few weeks to one month of consistent use, according to regulatory data.


Q: Can Artrozan be used long-term?

The oral formulation of Artrozan is approved for the management of chronic inflammatory conditions.

However, regulatory guidance consistently mandates that this class of medicine be used at the lowest effective dosage for the shortest duration necessary due to the potential for increased risk of serious side effects with prolonged use.


Q: What happens if I forget to take Artrozan?

According to patient information provided by regulatory bodies, the general instruction is to take a forgotten dose as soon as it is remembered.

If it is near the time for the next scheduled dose, the instruction is typically to skip the missed dose and resume the regular schedule. Regulatory guidance cautions against doubling doses to compensate for a missed one.


Q: Is Artrozan safe to take if I have high blood pressure?

Official safety documents state that Artrozan use requires caution in individuals who have pre-existing high blood pressure or fluid retention.

This is because medicines in this class may lead to the worsening of blood pressure or interfere with the action of certain blood pressure medications.


Q: Is Artrozan habit-forming or addictive?

Artrozan is not listed as a controlled substance by regulatory bodies in the jurisdiction of its prescribing documents.

Therefore, it is not classified as a habit-forming or addictive medicine.


Q: Is it normal to feel a little dizzy after starting Artrozan?

Dizziness is listed in the official safety documents as an uncommon adverse effect.

This means that while it is a documented reaction, it is not among the most frequently observed side effects.


Q: Can I take Artrozan if I am driving or operating machinery?

Official safety documentation lists side effects such as dizziness and somnolence (sleepiness).

Regulatory warnings indicate that patients who experience these or similar effects should use caution when performing tasks such as driving or operating machinery.


Q: How long after stopping Artrozan does it stay in my system?

Official pharmacokinetic data, which describes how the body processes the medicine, is provided in regulatory documents.

This data indicates that the elimination half-life is approximately 20 hours, which is the time required for the body to eliminate half of the dose.


Q: Can I use Artrozan for a sports injury or acute pain?

Official approvals designate the intravenous formulation for the short-term management of moderate-to-severe pain.

Conversely, the oral formulation is approved for treating chronic inflammatory conditions.


Q: Does Artrozan affect the kidneys or liver?

Official documents caution that the long-term use of medicines in this class has resulted in renal (kidney) injury in some cases.

Furthermore, regulatory documents note that use requires caution in patients who have pre-existing impaired renal or liver function.


Q: Are there any known issues combining Artrozan with blood thinners?

Official information indicates that Artrozan used alongside other anticoagulants (blood thinners) requires caution due to a documented increased risk of serious gastrointestinal bleeding.

Concomitant use with certain antiplatelet agents, such as Aspirin, is formally prohibited (contraindicated).


Q: Do studies suggest Artrozan is effective for treating back pain?

The approved indications listed in regulatory documents specify the management of certain forms of arthritis, such as osteoarthritis and rheumatoid arthritis.

Back pain is not explicitly listed as a standalone approved indication for Artrozan.


Q: Are there specific food restrictions while taking Artrozan?

Official product information states that the oral tablets can be taken with or without food.

The only commonly mentioned substance constraint is related to the use of alcohol, which is documented to increase the risk of gastrointestinal bleeding.


Q: What are the warning signs I should look for when taking Artrozan?

Official safety labeling indicates that prompt medical attention should be sought if signs of serious cardiovascular events, such as chest pain or sudden weakness, are experienced.

The same prompt medical attention is advised for the first sign of any hypersensitivity reaction, such as a skin rash.


Q: Does Artrozan cause changes in mood or sleep?

Official safety documentation lists somnolence (sleepiness) as a possible side effect.

Less frequently, reports of mood changes, including depression-related symptoms, have also been documented.


Q: Is Artrozan recommended for people with asthma?

Regulatory documents specify that Artrozan is formally contraindicated, meaning prohibited from use, in patients who have a history of asthma, hives (urticaria), or other allergic-type reactions after taking aspirin or other NSAIDs.


Q: Can young adults take Artrozan for chronic pain?

Official regulatory documents state that Artrozan is approved for standard labeled uses in the general Adult population.

This classification includes young adults and covers chronic inflammatory conditions that the medicine is approved to manage.


Q: Do official prescribing documents mention anything about long-term side effects?

Yes, official prescribing information explicitly discusses the relationship between the duration of use and the risk of certain serious side effects.

Specifically, the risk of cardiovascular thrombotic events and renal injury is documented to increase with the length of time the medicine is used.


Q: What types of pain conditions is Artrozan usually approved to treat?

According to official regulatory labeling, the medicine is approved to treat specific forms of arthritis.

These include osteoarthritis and rheumatoid arthritis in adults, as well as Juvenile Idiopathic Arthritis (JIA) in pediatric patients aged two years and older.


Q: Can Artrozan be taken with herbal remedies like turmeric or ginger?

While specific herbal remedies like turmeric or ginger are not typically listed in the main interaction documents, official patient labeling recommends that patients inform a healthcare provider about all vitamins, supplements, and herbs being taken.

This is a general precaution to ensure full oversight of all substances consumed.


Q: What if I'm already taking medicine for acid reflux; is Artrozan okay?

Artrozan carries a formal caution regarding the risk of serious gastrointestinal events, such as bleeding and ulceration.

While the core regulatory documents may not list specific acid reflux medicines as an interaction, caution is strongly advised for patients with any history of gastrointestinal issues.


Q: Can Artrozan be crushed or split?

Standard instructions for the oral tablet formulation typically direct that the medicine should be swallowed whole.

The tablets are generally intended not to be crushed, split, or chewed unless explicit instructions have been provided by a healthcare professional or pharmacist.


Q: Is Artrozan used for gout flares?

The official regulatory labeling for Artrozan does not list acute gout flares as one of its approved indications.

The medicine is primarily approved for the long-term management of specific forms of arthritis.


Q: Is Artrozan an 'over-the-counter' medicine somewhere?

Based on the official prescribing documents, Artrozan is classified as a prescription-only medicine in the jurisdiction of its approval.

It is not listed as an over-the-counter (OTC) drug.


Q: Does Artrozan affect contraception pills?

Official documents do contain documented interaction information regarding Artrozan and certain types of oral contraceptives.

This interaction may result in an increased risk of high potassium levels in the blood.


Q: Is it necessary to have routine blood tests while on Artrozan?

Clinical monitoring, potentially including laboratory tests such as those for hematopoietic or liver function, may be deemed appropriate by a healthcare provider.

This is often noted as a consideration during the course of chronic therapy.


Q: Is there a generic version of Artrozan available?

Yes, the active ingredient in Artrozan, which is Meloxicam, is available from multiple manufacturers.

This generic availability is the result of regulatory bodies approving Abbreviated New Drug Applications (ANDAs).


Q: Why do some people report feeling tired when they take Artrozan?

Official safety documentation lists fatigue and a general feeling of tiredness and weakness as adverse effects that have been reported by patients.

This is the documented basis for reports of tiredness while taking the medicine.


Q: Are there any known interactions between Artrozan and diabetes medication?

Yes, official interaction labeling documents that using Artrozan with insulin or certain other diabetes medications may be associated with an increased risk of hypoglycemia (low blood sugar).


Q: What should I do if I notice a skin rash after taking Artrozan?

Safety labeling indicates that if a skin rash or other initial signs of a hypersensitivity reaction are noticed, the medicine should be discontinued.

The documents also direct that prompt medical attention should be sought following this observation.


Q: Is Artrozan primarily for chronic conditions?

Artrozan is used for both chronic and acute conditions, depending on the formulation.

The oral formulation is approved for the management of chronic inflammatory conditions, while the intravenous formulation is approved for the short-term management of acute pain.


Q: What is the usual duration of a treatment cycle with Artrozan?

The official documents specify that the intravenous formulation is designated for short-term use only.

While the oral formulation is for chronic conditions, regulatory guidance directs that treatment should be limited to the shortest duration necessary to achieve symptomatic relief.

How should Artrozan be stored and disposed of?

How to Store and Dispose of Artrozan

Official Storage Conditions

Artrozan (meloxicam) tablets must be stored at Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be kept from freezing and protected from excessive heat, moisture, and light. To maintain stability until the expiry date, keep the medicine in its original package and ensure the container is tightly closed.

Handling and Disposal

It is mandatory to keep Artrozan out of the reach of children. Do not keep or use outdated medicine. When disposing of unused or expired tablets, do not flush them down the toilet or throw them into household trash. Instead, ask a pharmacist or healthcare professional for instructions on proper disposal, which is typically through a medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Artrozan found in:

A-Z Index: